Abstract Background: the vascular endothelial growth factor (VEGF) pathway plays a prominent role in the growth and progression of human cancer, including non-small cell lung carcinoma (NSCLC). The key mediators…
Abstract Historical data have indicated the potential for the histologically-normal breast to harbor pre-malignant changes at the molecular level. We postulated that a histologically-normal tissue with ‘‘tumor-like’’ gene expression pattern…
Abstract We recently developed a malignancy-risk gene signature that was shown to identify histologically-normal tissues with a cancer-like profile. Because the signature was rich with proliferative genes, we postulated it…
Abstract Background: A postgraduate training program should be focused on positive and healthy educational environment. Postgraduate trainees suffer invariably during their training when the hospital educational environment is stressful. It…
Abstract Treatment of metastatic gastric cancer typically involves chemotherapy and monoclonal antibodies targeting HER2 (ERBB2) and VEGFR2 (KDR). However, reliable methods to identify patients who would benefit most from a…
Abstract. Background: The vascular endothelial growth factor (VEGF) pathway plays an important role in growth and progression of human cancer, including colorectal carcinomas (CRC). The key mediators of VEGF signaling…
Background: The expression of somatostatin receptors (SSTRs) on endocrine tumor (ET) cells forms the basis for somatostatin analog treatment of patients with SSTR-positive, hormonally active ETs. In patients with SSTRnegative…
Abstract Background: Clinically relevant predictive biomarkers to tailor anti-angiogenic therapies to breast cancer (BRC) patient subpopulations are an unmet need.Methods: We analyzed tumor vascular density and VEGFR2 protein expression in…
Abstract Background Ramucirumab (RAM), a monoclonal antibody for vascular endothelial growth factor 2 (VEGFR2), has been effective for advanced gastric adenocarcinoma (AC). However, little is known about the efficacy of…
Identification of the site of origin for ‘malignancy with unknown primary’ remains a challenge for modern pathology. Correct diagnosis is critical to defining the most beneficial treatment for the patient.…